Mezzion Pharma (140410) Fundamentals 2026 — Revenue Analysis | SniperIQ
Mezzion Pharma (140410) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩1.56T, trading at ₩51300.00 on the KOE. This SniperIQ fundamentals page covers Mezzion Pharma's valuation, profitability (net margin -463.2%), revenue (₩7.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mezzion Pharma's market cap?
Mezzion Pharma (140410) has a market capitalization of approximately ₩1.56T, trading at ₩51300.00 on the KOE. Market cap moves with the live share price.
What is Mezzion Pharma's P/E ratio?
Mezzion Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 100.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mezzion Pharma?
Mezzion Pharma runs a net profit margin of -463.2%, a gross margin of 5.8%, and an operating margin of -161.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mezzion Pharma generate?
Mezzion Pharma reported revenue of ₩7.9B for fiscal year 2025, with net income of -₩34.9B and earnings per share (EPS) of -1150.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mezzion Pharma pay a dividend?
Mezzion Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Mezzion Pharma financially healthy?
Mezzion Pharma carries a debt-to-equity ratio of 0.80x and a current ratio of 0.47x, with a market beta of 1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mezzion Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mezzion Pharma (140410) the key facts are: market cap ₩1.56T, revenue ₩7.9B, 52-week range 35850-179900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mezzion Pharma's full fundamentals live
Get Mezzion Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.